KalVista Pharmaceuticals, Inc. (KALV)

Market Cap	660.34M
Revenue (ttm)	1.43M
Net Income (ttm)	-203.10M
Shares Out	50.52M
EPS (ttm)	-3.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	93,825
Open	13.12
Previous Close	13.10
Day's Range	12.94 - 13.27
52-Week Range	7.30 - 17.28
Beta	-0.10
Analysts	Strong Buy
Price Target	26.43 (+102.22%)
Earnings Date	Sep 11, 2025

About KALV

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use ...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Benjamin Palleiko
• Employees: 270
• Stock Exchange: NASDAQ
• Ticker Symbol: KALV
• Website: https://www.kalvista.com

Analyst Summary

According to 8 analysts, the average rating for KALV stock is "Strong Buy." The 12-month stock price target is $26.43, which is an increase of 102.22% from the latest price.

Price Target

$26.43

(102.22% upside)

Analyst Consensus: Strong Buy